MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosis

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 846-852

  Jasinski, Piotr ^a,b   Zwolak, Pawel ^a   Vogel, Rachel Isaksson ^c   Bodempudi, Vidya ^a   Terai, Kaoru ^a   Galvez, Jorge ^d   Land, David ^e   Dudek, Arkadiusz Z ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF VALENCIA   (Spain)

^e Medisyn Technologies Inc   (United States)

Author keywords

In vivo antitumor activity; In vivo toxicity; MT103; New drug development

Indexed keywords

BLINATUMOMAB; CISPLATIN; NANOPARTICLE; PROTEIN KINASE C; BORNANE DERIVATIVE; ISOBORNEOL; N,N DICYCLOHEXYL ISOBORNEOL 10 SULFONAMIDE; N,N-DICYCLOHEXYL-ISOBORNEOL-10-SULFONAMIDE; SULFONAMIDE;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DNA FRAGMENTATION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FIBROBLAST; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUNG CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL; TIME; TUMOR CELL LINE; ULTRASTRUCTURE;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; BORNANES; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MICE; PROTEIN KINASE C; SULFONAMIDES; SURVIVAL ANALYSIS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856067653     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9432-4     Document Type: Article

References (13)

1. Galvez J, Garcia-Domenech R, de Julian-Ortiz JV, Soler R (1995) Topological approach to drug design. J Chem Inf Comput sci 35(2):272-84
2. Garcia-Domenech R, Galvez J, de Julian-Ortiz JV, Pogliani L (2008) Some new trends in chemical graph theory. Chem Rev 108(3):1127-69
3. Jasinski P, Zwolak P, Terai K, Dudek AZ (2008) Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo. Transl Res 152(5):203-12
4. Jasinski P, Welsh B, Galvez J et al (2008) A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines. Invest New Drugs 26(3):223-32
5. Llompart J, Galvez J (2005) Inventors; US Patent 20056919376
6. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev 6(10):813-23
7. Stinson SF, Alley MC, Kopp WC et al (1992) Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 12(4):1035-53
8. Dudek AZ, Bodempudi V, Welsh BW et al (2007) Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy. Br J Cancer 97(4):513-22
9. D'Argenio D (1997) Adapt II user's guide: Pharmacokinetic/pharmacodynamic system analysis software. Biomedical Simulations Resource, Los Angeles
10. Pui D Y H, Chen D-R (2004) Inventor Electrospraying Apparatus and Method for Coating Particles patent US Patent#6, 746, 869. June 8, 2004
11. Pui D Y H, Chen D-R (2000) inventor Electrospraying Apparatus and Method for Introducing Material into Cells patent US Patent #6, 093, 557. July 25, 2000
12. Kaplan E L M P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
13. Dudek AZ, Zwolak P, Jasinski P, Terai Kaoru, Gallus NJ, Ericson ME, Farassati F (2007) Protein kinase C-β inhibitor enzastaurin (LY317615. HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest New Drugs, August 6